Imperial College London

Professor Alan Fenwick OBE

Faculty of MedicineSchool of Public Health

Professor of Tropical Parasitology
 
 
 
//

Contact

 

+44 (0)20 7594 3418a.fenwick Website

 
 
//

Assistant

 

Mrs Christine Logan +44 (0)20 7594 3287

 
//

Location

 

VB1Norfolk PlaceSt Mary's Campus

//

Summary

 

Summary

Professor Fenwick directs the Schistosomiasis Control Initiative (SCI) in the Department of Infectious Disease Epidemiology.

The SCI is a collaborative project to assist countries in sub Saharan Africa control schistosomiasis, intestinal helminths and other Neglected Tropical Diseases (NTDs). The SCI was awarded a prestigous Queens Anniversary Prize (2008), and a medal and certificate were collected from Buckingham Palace on February 14th 2008.

During 2013 SCI reached the milestone of having assisted in the delivery of 100 million treatments against schistoisomiasis in Africa and the Middle East

Schistosomiasis is a parasitic disease that leads to chronic ill-health and affects more than 200 million people in developing countries, 85% of them in sub-Saharan Africa. Approximately 600 million people are at risk of contracting schistosomiasis because they live in tropical regions where water supply and sanitation are inadequate or non-existent.

The SCI was originally supported by the Bill and Melinda Gates Foundation, through several grants since 2002, for work in six countries, Burkina Faso, Mali, Niger, Tanzania (including Zanzibar), Uganda and Zambia, and for research into cysticercosis. In 2007, Geneva Global awarded funds for control work in Rwanda and Burundi - with new funding both countries are still receiving support . SCI works in partnership with the World Health Organisation. SCI participated in the USAID/NTD control project as country managers for Burkina Faso, Niger and Uganda from 2006-2011. SCI is a technical assistance partner in the World Bank funded project to control schistosomiasis in Yemen, and is a partner in the SCORE project managing their programmes in Mozambique and Niger.

SCI's current major funding sources are the 2010 and 2014 awards by DFID (UK) to deliver 200 million treatments against schistosomiasis and STH over 5 years to 10 countries in Africa. Other donors include the ENDFUND and many private donors who we hope will allow us to reach 300 million treatments delivered by 2019.

SCI is recommended as top charity by www.givingwhatwecan.org in UK, and is one of the top international charities recommended by www.givewell.org in USA. Donations may be through our website http://www3.imperial.ac.uk/schisto where our funds are held by the College in a ringfenced account. Donors can also donate via the Charity IC TRUST (Charity Number 273071), but in both cases please specify the funds are for SCI. Donated funds are used for treatment of schistosomiasis with praziquantel and intestinal worms with Albendazole at an average cost of less than 50 pence per child per year.

Further information on this unique programme can be found on the SCI website at http://www3.imperial.ac.uk/schisto . 

 Global Health Course - June 2008 onwards

I am a course director for a short course first run in June 2008. The course uses top faculty to give an overview of Global health

imageThe course has been repeated annually and in 2013 the attendance was over 70 participants including health professionals plus students from Imperial, other UK and international universities. Participants explored the complex issues of global health including health inequalities, health systems, the impact of climate change, globalisation, migration, newly emerging infections, conflict and humanitarian interventions. Participants have the opportunity to join a debate on the role of pharmaceutical companies in global health. The online student evaluation was excellent.  For discussion and to keep in touch why not join our facebook group?

Publications

Chami GF, Kontoleon AA, Bulte E, et al., 2016, Profiling Nonrecipients of Mass Drug Administration for Schistosomiasis and Hookworm Infections: A Comprehensive Analysis of Praziquantel and Albendazole Coverage in Community-Directed Treatment in Uganda, Clinical Infectious Diseases, Vol:62, ISSN:1058-4838, Pages:200-207

Fenwick A, Jourdan P, 2016, Schistosomiasis elimination by 2020 or 2030?, International Journal For Parasitology, Vol:46, ISSN:0020-7519, Pages:385-388

Ezeamama AE, He C-L, Shen Y, et al., 2016, Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries, Bmc Infectious Diseases, Vol:16, ISSN:1471-2334

Knopp S, Person B, Ame SM, et al., 2016, Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey., Parasit Vectors, Vol:9

French MD, Churcher TS, Webster JP, et al., 2015, Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in countries with schistosomiasis control initiative-assisted programmes, Parasites & Vectors, Vol:8, ISSN:1756-3305

More Publications